Login to Your Account



Apricus fizzles after fispemifene fails to impress in phase IIb trial

By Marie Powers
News Editor

Monday, March 28, 2016

Apricus Biosciences Inc. is halting development of fispemifene after the SERM failed to achieve statistical significance in the primary endpoint of erectile function or the secondary endpoint of low libido in a phase IIb proof-of-concept study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription